Challenges and best practices for hepatitis C care among people who inject drugs in resource limited settings: focus group discussions with healthcare providers in Kenya

References

• Akiyama, M. J., Cleland, C. M., Lizcano, J. A., Cherutich, P., & Kurth, A. E. (2019). Prevalence, estimated incidence, risk behaviours, and genotypic distribution of hepatitis C virus among people who inject drugs accessing harm-reduction services in Kenya: A retrospective cohort study. The Lancet Infectious Diseases, 19(11), 1255–1263. https://doi.org/10.1016/S1473-3099(19)30264-6
   PubMed Web of Science ®Google Scholar
• Akiyama, M. J., Muller, A., Huang, O., Lizcano, J., Nyakowa, M., Riback, L., Ross, J., Bundi, H., Kulabi, E. S., Mwangi, A. M., Musyoki, H., Cherutich, P., & Kurth, A. (2021). Hepatitis C-related knowledge, attitudes and perceived risk behaviours among people who inject drugs in Kenya: A qualitative study. Global Public Health, 17(6), 1016–1028. https://doi.org/10.1080/17441692.2021.1896763.
   PubMed Web of Science ®Google Scholar
• Akiyama, M. J., Norton, B. L., Arnsten, J. H., Agyemang, L., Heo, M., & Litwin, A. H. (2019). Intensive models of hepatitis C care for people who inject drugs receiving opioid agonist therapy: A randomized controlled trial. Annals of Internal Medicine, 170(9), 594–603. https://doi.org/10.7326/M18-1715
   PubMed Web of Science ®Google Scholar
• Akiyama, M. J., Riback, L. R., Nyakowa, M., Musyoki, H., Lizcano, J. A., Muller, A., Zhang, C., Walker, J. G., Stone, J., Vickerman, P., Cherutich, P., & Kurth, A. E. (2022). Hepatitis C treatment outcomes among people who inject drugs accessing harm reduction settings in Kenya. Journal of Viral Hepatitis, 29(8), 691–694. https://doi.org/10.1111/jvh.13662
   PubMed Web of Science ®Google Scholar
• Amoako, A., Ortiz-Paredes, D., Engler, K., Lebouche, B., & Klein, M. B. (2021). Patient and provider perceived barriers and facilitators to direct acting antiviral hepatitis C treatment among priority populations in high income countries: A knowledge synthesis. International Journal of Drug Policy, 96, 103247. https://doi.org/10.1016/j.drugpo.2021.103247
   PubMed Web of Science ®Google Scholar
• Ayieko, J., Brown, L., Anthierens, S., Van Rie, A., Getahun, M., Charlebois, E. D., Petersen, M. L., Clark, T. D., Kamya, M. R., Cohen, C. R., Bukusi, E. A., Havlir, D. V., & Camlin, C. S. (2018). “Hurdles on the path to 90-90-90 and beyond”: qualitative analysis of barriers to engagement in HIV care among individuals in rural East Africa in the context of test-and-treat. PLoS One, 13(8), e0202990. https://doi.org/10.1371/journal.pone.0202990
   PubMed Web of Science ®Google Scholar
• Ayon, S., Ndimbii, J., Jeneby, F., Abdulrahman, T., Mlewa, O., Wang, B., Ragi, A., & Mburu, G. (2018). Barriers and facilitators of access to HIV, harm reduction and sexual and reproductive health services by women who inject drugs: Role of community-based outreach and drop-in centers. AIDS Care, 30(4), 480–487. https://doi.org/10.1080/09540121.2017.1394965
   PubMed Web of Science ®Google Scholar
• Beckerleg, S., Telfer, M., & Hundt, G. L. (2005). The rise of injecting drug use in East Africa: A case study from Kenya. Harm Reduction Journal, 2(1), 12. https://doi.org/10.1186/1477-7517-2-12
   PubMedGoogle Scholar
• Bregenzer, A., Conen, A., Knuchel, J., Friedl, A., Eigenmann, F., Näf, M., Ackle, P., Roth, M., & Fux, C. A. (2017). Management of hepatitis C in decentralised versus centralised drug substitution programmes and minimally invasive point-of-care tests to close gaps in the HCV cascade. Swiss Medical Weekly, 147, w14544. https://doi.org/10.4414/smw.2017.14544
   PubMed Web of Science ®Google Scholar
• Brener, L., Wilson, H., Slavin, S., & de Wit, J. (2013). The impact of living with HIV: Differences in experiences of stigma for heterosexual and homosexual people living with HIV in Australia. Sexual Health, 10(4), 316–319. https://doi.org/10.1071/SH12170
   PubMed Web of Science ®Google Scholar
• Butner, J. L., Gupta, N., Fabian, C., Henry, S., Shi, J. M., & Tetrault, J. M. (2017). Onsite treatment of HCV infection with direct acting antivirals within an opioid treatment program. Journal of Substance Abuse Treatment, 75, 49–53. https://doi.org/10.1016/j.jsat.2016.12.014
   PubMed Web of Science ®Google Scholar
• Degenhardt, L., Peacock, A., Colledge, S., Leung, J., Grebely, J., Vickerman, P., Stone, J., Cunningham, E. B., Trickey, A., Dumchev, K., Lynskey, M., Griffiths, P., Mattick, R. P., Hickman, M., & Larney, S. (2017). Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: A multistage systematic review. The Lancet Global Health, 5(12), e1192–e1207. https://doi.org/10.1016/S2214-109X(17)30375-3
   PubMed Web of Science ®Google Scholar
• Dhiman, R. K., & Premkumar, M. (2020). Hepatitis C virus elimination by 2030: Conquering mount improbable. Clinical Liver Disease, 16(6), 254–261. https://doi.org/10.1002/cld.978
   Google Scholar
• Easterbrook, P. J., & Group, W. H. O. G. D. (2016). Who to test and how to test for chronic hepatitis C infection – 2016 WHO testing guidance for low- and middle-income countries. Journal of Hepatology, 65(1 Suppl), S46–S66. https://doi.org/10.1016/j.jhep.2016.08.002
   PubMedGoogle Scholar
• (EMCDDA) EMCfDaDA. (2019). New models of care for drugs service.
   Google Scholar
• Folch, C., Saludes, V., Reyes-Urena, J., Reyes-Ureña, J., Antuori, A., Ibáñez, N., Majó, X., Colom, J., Matas, L., Casabona, J., & Martró, E. (2021). The hepatitis C care cascade among people who inject drugs accessing harm reduction services in Catalonia: Major gaps for migrants. International Journal of Drug Policy, 90, 103057. https://doi.org/10.1016/j.drugpo.2020.103057
   PubMed Web of Science ®Google Scholar
• Graham, C. S., & Swan, T. (2015). A path to eradication of hepatitis C in low- and middle-income countries. Antiviral Research, 119, 89–96. https://doi.org/10.1016/j.antiviral.2015.01.004
   PubMed Web of Science ®Google Scholar
• Grebely, J., Dalgard, O., Conway, B., Cunningham, E. B., Bruggmann, P., Hajarizadeh, B., Amin, J., Bruneau, J., Hellard, M., Litwin, A. H., Marks, P., Quiene, S., Siriragavan, S., Applegate, T. L., Swan, T., Byrne, J., Lacalamita, M., Dunlop, A., Matthews, G. V., … Dore, G. J. (2018). Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial. The Lancet Gastroenterology & Hepatology, 3(3), 153–161. https://doi.org/10.1016/S2468-1253(17)30404-1
   PubMed Web of Science ®Google Scholar
• Guidelines for the Treatment of Chronic Hepatitis B and C Viral Infections in Kenya. (n.d.). Republic of Kenya: Gastroenterology Society of Kenya. http://publications.universalhealth2030.org/uploads/kenya-national-hepatitisguidelines-2014.pdf http://guidelines.health.go.ke:8000/media/kenya-national-hepatitis-guidelines-2014.pdf.
   Google Scholar
• Gwadz, M., Leonard, N. R., Honig, S., Freeman, R., Kutnick, A., & Ritchie, A. S. (2018). Doing battle with “the monster”: How high-risk heterosexuals experience and successfully manage HIV stigma as a barrier to HIV testing. International Journal for Equity in Health, 17(1), 46. https://doi.org/10.1186/s12939-018-0761-9
   PubMedGoogle Scholar
• Ha, S., & Timmerman, K. (2018). Awareness and knowledge of hepatitis C among health care providers and the public: A scoping review. Canada Communicable Disease Report, 44(7-8), 157–165. https://doi.org/10.14745/ccdr.v44i78a02
   PubMedGoogle Scholar
• Hill, A., Khoo, S., Fortunak, J., Simmons, B., & Ford, N. (2014). Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries. Clinical Infectious Diseases, 58(7), 928–936. https://doi.org/10.1093/cid/ciu012
   PubMed Web of Science ®Google Scholar
• Kurth, A. E., Cleland, C. M., Des Jarlais, D. C., Musyoki, H., Lizcano, J. A., Chhun, N., & Cherutich, P. (2015). HIV prevalence, estimated incidence, and risk behaviors among people who inject drugs in Kenya. JAIDS Journal of Acquired Immune Deficiency Syndromes, 70(4), 420–427. https://doi.org/10.1097/QAI.0000000000000769
   PubMed Web of Science ®Google Scholar
• Lim, A. G., Trickey, A., & Vickerman, P. (2019). Screening strategies for Hepatitis C virus. Hepatology Communications, 3(3), 321–324. https://doi.org/10.1002/hep4.1330
   PubMed Web of Science ®Google Scholar
• Ludwig-Barron, N. T., Guthrie, B. L., Mbogo, L., Bukusi, D., Sinkele, W., Gitau, E., Farquhar, C., & Monroe-Wise, A. (2021). Barriers and facilitators of HIV and hepatitis C care among people who inject drugs in Nairobi, Kenya: A qualitative study with peer educators. Harm Reduction Journal, 18(1), 133. https://doi.org/10.1186/s12954-021-00580-7
   PubMed Web of Science ®Google Scholar
• Lule, G. N., & Nyawira, B. (2016). Guidelines for the Treatment of Chronic Hepatitis B and C Viral Infections in Kenya. Gastroenterology Society of Kenya. Government Of Kenya.
   Google Scholar
• Mburu, G., Ayon, S., Tsai, A. C., Ndimbii, J., Wang, B., Strathdee, S., & Seeley, J. (2018). Who has ever loved a drug addict? It's a lie. They think a ‘teja’ is as bad person": multiple stigmas faced by women who inject drugs in coastal Kenya. Harm Reduction Journal, 15(1), 29. https://doi.org/10.1186/s12954-018-0235-9
   PubMedGoogle Scholar
• McGowan, C. E., Monis, A., Bacon, B. R., Mallolas, J., Goncales, F. L., Goulis, I., Poordad, F., Afdhal, N., Zeuzem, S., Piratvisuth, T., Marcellin, P., & Fried, M. W. (2013). A global view of hepatitis C: Physician knowledge, opinions, and perceived barriers to care. Hepatology, 57(4), 1325–1332. https://doi.org/10.1002/hep.26246
   PubMed Web of Science ®Google Scholar
• McLeroy, K. R., Bibeau, D., Steckler, A., & Glanz, K. (1988). An ecological perspective on health promotion programs. Health Education Quarterly, 15(4), 351–377. https://doi.org/10.1177/109019818801500401
   PubMedGoogle Scholar
• Mohamed, Z., Mbwambo, J., Rwegasha, J., Mgina, N., Doulla, B., Mwakale, P., Tuaillon, E., Chevaliez, S., Shimakawa, Y., Taylor-Robinson, S. D., Thursz, M. R., Brown, A. S., & Lemoine, M. (2020). In-field evaluation of Xpert(R) HCV viral load Fingerstick assay in people who inject drugs in Tanzania. Liver International, 40(3), 514–521. https://doi.org/10.1111/liv.14315
   PubMed Web of Science ®Google Scholar
• Morgan, J. R., Servidone, M., Easterbrook, P., & Linas, B. P. (2017). Economic evaluation of HCV testing approaches in low and middle income countries. BMC Infectious Diseases, 17(Suppl 1), 697. https://doi.org/10.1186/s12879-017-2779-9
   PubMedGoogle Scholar
• Nelson, P. K., Mathers, B. M., Cowie, B., Hagan, H., Des Jarlais, D., Horyniak, D., & Degenhardt, L. (2011). Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: Results of systematic reviews. The Lancet, 378(9791), 571–583. https://doi.org/10.1016/S0140-6736(11)61097-0
   PubMed Web of Science ®Google Scholar
• Rao, V. B., Johari, N., du Cros, P., Messina, J., Ford, N., & Cooke, G. S. (2015). Hepatitis C seroprevalence and HIV co-infection in sub-Saharan Africa: A systematic review and meta-analysis. The Lancet Infectious Diseases, 15(7), 819–824. https://doi.org/10.1016/S1473-3099(15)00006-7
   PubMed Web of Science ®Google Scholar
• Rhodes, T., Guise, A., Ndimbii, J., Strathdee, S., Ngugi, E., Platt, L., Kurth, A., Cleland, C., & Vickerman, P. (2015). Is the promise of methadone Kenya's solution to managing HIV and addiction? A mixed-method mathematical modelling and qualitative study. BMJ Open, 5(3), e007198. https://doi.org/10.1136/bmjopen-2014-007198
   PubMed Web of Science ®Google Scholar
• Skolnik, A. A., Noska, A., Yakovchenko, V., Tsai, J., Jones, N., Gifford, A. L., & McInnes, D. K. (2019). Experiences with interferon-free hepatitis C therapies: Addressing barriers to adherence and optimizing treatment outcomes. BMC Health Services Research, 19(1), 91. https://doi.org/10.1186/s12913-019-3904-9
   PubMedGoogle Scholar
• Sonderup, M. W., Afihene, M., Ally, R., Apica, B., Awuku, Y., Cunha, L., Dusheiko, G., Gogela, N., Lohouès-Kouacou, M.-J., Lam, P., Lesi, O., Mbaye, P. S., Musabeyezu, E., Musau, B., Ojo, O., Rwegasha, J., Scholz, B., Shewaye, A. B., Tzeuton, C., … Spearman, C. W. (2017). Hepatitis C in sub-Saharan Africa: The current status and recommendations for achieving elimination by 2030. The Lancet Gastroenterology & Hepatology, 2(12), 910–919. https://doi.org/10.1016/S2468-1253(17)30249-2
   PubMed Web of Science ®Google Scholar
• Ti, L., Socias, M. E., Wood, E., Milloy, M.-J., Nosova, E., DeBeck, K., Kerr, T., & Hayashi, K. (2018). The impact of methadone maintenance therapy on access to regular physician care regarding hepatitis C among people who inject drugs. PLoS One, 13(3), e0194162. https://doi.org/10.1371/journal.pone.0194162
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO). (2016). Global health sector strategy on viral hepatitis 2016–2021.
   Google Scholar
• World Health Organization (WHO). (2017). Global hepatitis report, 2017.
   Google Scholar
• World Health Organization (WHO). (2021). Global progress report on HIV, viral hepatitis and sexually transmitted infections. Retrieved November 1, 2021, from https://www.who.int/publications/i/item/9789240027077.
   Google Scholar
• World Health Organization (WHO). (n.d). Access to hepatitis C testing and treatment for people who inject drugs and people in prisons – a global perspective: policy brief. https://apps.who.int/iris/handle/10665/312116.
   Google Scholar
• Yuh, J. N., Ellwanger, K., Potts, L., & Ssenyonga, J. (2014). Stigma among HIV/AIDS patients in Africa: A critical review. Procedia - Social and Behavioral Sciences, 140, 581–585. https://doi.org/10.1016/j.sbspro.2014.04.474
   Google Scholar